Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Ruhr University of Bochum |
---|---|
Information provided by: | Ruhr University of Bochum |
ClinicalTrials.gov Identifier: | NCT00751504 |
Atypical antipsychotics have been found not only to be beneficial in the treatment of psychotic disorders, but even for depressive symptoms in patients with schizophrenia. Remarkably, preliminary data suggest that the atypical antipsychotic quetiapine has antidepressive properties. Until now, there is limited knowledge concerning the efficacy of quetiapine in major depressive illness and especially in psychotic depression. In our own clinical practice, several patients with psychotic depression were successfully treated with quetiapine as add-on therapy or as monotherapy. On the background of that, the convincing effects of quetiapine in bipolar depression, single-case reports and pilot studies concerning its effectiveness in depressive mood states in psychotic disorders as well as our clinical experiences, it is to assume that a treatment with quetiapine over a 6 weeks period show similar effects in major depressive episode with psychotic features, i.e. psychotic depression. In this pilot study we plan to investigate 20 patients with psychotic features of depression under treatment with quetiapine.
Condition | Intervention | Phase |
---|---|---|
Psychotic Depression |
Drug: Quetiapine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Quetiapine in the Treatment of Psychotic Depression - a Pilot Study |
Estimated Enrollment: | 20 |
Study Start Date: | September 2008 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany, NRW | |
LWL University Hospital Bochum of the Ruhr-University Bochum | Recruiting |
Bochum, NRW, Germany, 44791 | |
Contact: Georg Juckel, M.D., Ph.D. 00492345077202 georg.juckel@wkp-lwl.org | |
Principal Investigator: Georg Juckel, M.D., Ph.D. | |
Sub-Investigator: Hans-Jörg Assion, M.D. | |
Sub-Investigator: Nina Ansorge, M.D. | |
Sub-Investigator: Idun Uhl, M.D. | |
Sub-Investigator: Heinrich von Reventlow, M.Sc. |
Principal Investigator: | Georg Juckel, M.D., Ph.D. | LWL University Hospital Bochum |
Responsible Party: | LWL University Hospital Bochum ( Prof. Dr. med. Georg Juckel ) |
Study ID Numbers: | D1443L00040 |
Study First Received: | September 11, 2008 |
Last Updated: | September 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00751504 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Quetiapine Psychotic depression |
Tranquilizing Agents Depression Bipolar Disorder Psychotropic Drugs Central Nervous System Depressants Depressive Disorder, Major Depressive Disorder Antipsychotic Agents |
Behavioral Symptoms Schizophrenia Affective Disorders, Psychotic Quetiapine Mental Disorders Mood Disorders Psychotic Disorders Schizophrenia and Disorders with Psychotic Features |
Depression Tranquilizing Agents Bipolar Disorder Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Depressive Disorder, Major Depressive Disorder Antipsychotic Agents Pharmacologic Actions |
Behavioral Symptoms Affective Disorders, Psychotic Quetiapine Mental Disorders Therapeutic Uses Mood Disorders Psychotic Disorders Central Nervous System Agents Schizophrenia and Disorders with Psychotic Features |